SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

BACKGROUND: In preclinical Ewing sarcoma (ES) models, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with synergy in combination with cytotoxic agents. This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Chugh, Rashmi, Ballman, Karla V., Helman, Lee J., Patel, Shreyaskumar, Whelan, Jeremy S., Widemann, Brigitte, Lu, Yao, Hawkins, Douglas S., Mascarenhas, Leo, Glod, John W., Ji, Jiuping, Zhang, Yiping, Reinke, Denise, Strauss, Sandra J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246769/
https://ncbi.nlm.nih.gov/pubmed/33289920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33349
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars